Q2 2016 13F Holders as of 6/30/2016
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
28M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
3.03M
-
Shares change
-
+3.03M
-
Total reported value, excl. options
-
$37.8M
-
Value change
-
+$37.8M
-
Number of buys
-
1
-
Price
-
$12.50
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q2 2016
1 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value as of Q2 2016.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.03M shares
of 28M outstanding shares and own 10.81% of the company stock.
Largest 10 shareholders include FMR LLC (3.03M shares), Flagship Ventures Fund IV General Partner LLC (4.81M shares), DEERFIELD MANAGEMENT CO (2.1M shares), Redmile Group, LLC (946K shares), Aisling Capital LLC (909K shares), BAKER BROS. ADVISORS LP (204K shares), EVENTIDE ASSET MANAGEMENT, LLC (150K shares), Foresite Capital Management III, LLC (150K shares), Alyeska Investment Group, L.P. (70K shares), and Casdin Capital, LLC (50K shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.